Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection. Intercept’s CEO ...
Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a trial.
Avinash Dixit, John J. F. Sherrerd '52 University Professor of Economics at Princeton University, is John Nash's colleague and friend. He has taught economics courses on games of strategy, and written ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results